Literature DB >> 6131609

Phenothiazine protection in calcium overload-induced heart failure: a possible role for calmodulin.

S W Schaffer, K P Burton, H P Jones, H H Oei.   

Abstract

The effect of several phenothiazines on the extent of cellular damage resulting from the calcium paradox was examined. Hearts treated with trifluoperazine, a potent calmodulin inhibitor, exhibited less cellular damage than untreated myocardium as reflected by light microscopy, high-energy phosphate content and the loss of protein and creatine phosphokinase into the perfusate. A dose response of this effect revealed a maximal response at about 1 microM trifluoperazine, a concentration which lies well within the range generally attributed to calmodulin inhibition. Several other lines of evidence were also obtained suggesting a possible role for calmodulin in calcium-overload induced necrosis. First, the phenothiazines had little influence on membrane changes believed responsible for altered calcium permeability. Second, trifluoperazine was without major effect unless included in the reperfusion buffer, indicating that the drug is only effective during the phase associated with calcium overload. Finally, less protection was afforded hearts exposed to phenothiazines such as chlorpromazine and promethazine, which are weaker inhibitors of calmodulin, than those treated with the potent inhibitor trifluoperazine. While other interpretations are possible, these studies are consistent with a role for calmodulin in calcium overload-induced heart failure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6131609     DOI: 10.1152/ajpheart.1983.244.3.H328

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

1.  The possible role of phospholipase A2 in cardiac membrane destabilization under calcium overload conditions.

Authors:  M E Saxon; A K Filippov; U I Porotikov
Journal:  Basic Res Cardiol       Date:  1984 Nov-Dec       Impact factor: 17.165

2.  Anti-ischemic and membrane stabilizing activity of calmodulin inhibitors.

Authors:  A Beresewicz
Journal:  Basic Res Cardiol       Date:  1989 Nov-Dec       Impact factor: 17.165

3.  Comparison of the calcium entry and calcium overload blocking properties of R71811 and flunarizine.

Authors:  Y Matsui; I Yamagami; K Hirai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-09       Impact factor: 3.000

4.  Normothermic ischaemic cardiac arrest of the isolated perfused rat heart: effects of trifluoperazine and lysolecithin on mechanical and metabolic recovery.

Authors:  A Lochner; I van Niekerk; J C Kotzé
Journal:  Basic Res Cardiol       Date:  1985 Jul-Aug       Impact factor: 17.165

5.  Moderation of myocardial ischemia reperfusion injury by calcium channel and calmodulin receptor inhibition.

Authors:  Y Kimura; R M Engelman; J Rousou; J Flack; J Iyengar; D K Das
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

6.  Divalent cation channels activated by phenothiazines in membrane of rat ventricular myocytes.

Authors:  T Lefevre; E Coraboeuf; A Ghazi; A Coulombe
Journal:  J Membr Biol       Date:  1995-09       Impact factor: 1.843

7.  Chlorpromazine-induced cardiomyopathy in rats.

Authors:  K Saito; K Daitoku; H Fukunaga; T Matsuoka; S Biroh; M Kakei; T Kashima; H Tanaka
Journal:  Heart Vessels Suppl       Date:  1985

8.  Effects of calcium, calcium entry blockers and calmodulin inhibitors on atrioventricular conduction disturbances induced by hypoxia.

Authors:  T Anno; I Kodama; S Shibata; J Toyama; K Yamada
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

9.  Effect of calmodulin antagonists on hypoxia and reoxygenation damage in isolated rabbit hearts.

Authors:  A Beresewicz; E Karwatowska-Kryńska
Journal:  Basic Res Cardiol       Date:  1986 May-Jun       Impact factor: 17.165

10.  Effects of trifluoperazine and chlorpromazine on calcium-repleted injury in isolated ventricle strips.

Authors:  K Okumura; K Ogawa; T Satake
Journal:  Basic Res Cardiol       Date:  1985 Sep-Oct       Impact factor: 17.165

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.